Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

• Published in: Blood Vol. 122; no. 21; p. 871
• Main Authors: Flynn, Joseph M.M., Andritsos, Leslie A., Jones, Jeffrey A., Johnson, Amy J., Maddocks, Kami, Wiley, Elizabeth, Small, Karen, Im, Eun Kyung, Grever, Michael R., Bannerji, Rajat, Byrd, John C., Zhou, Honghong
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 15.11.2013

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults. While the breadth of therapies for this incurable disorder has increased recently, patients afflicted with high risk disease have few and predominantly unsatisfactory options. Cyclin-dependent kinase (CDKs) inhibitors, such as...